If adherence to self-injected TNF inhibitors for RA becomes a quality measure for health plans, it is important that the threshold is set using an evidence-driven approach so that outcomes are maximized if a higher threshold is needed, and providers are not unfairly penalized if a lower threshold is needed. This evidence concerns the gene TNF and rheumatoid arthritis.